JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2006) 191, 189-195       DOI: 10.1677/joe.1.06924
© 2006 Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rybczynska, A.
Right arrow Articles by Drewnowska, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rybczynska, A.
Right arrow Articles by Drewnowska, K.

Hypertensive effect of calcilytic NPS 2143 administration in rats

Apolonia Rybczynska, Artur Lehmann, Anna Jurska-Jasko, Konrad Boblewski, Czeslawa Orlewska1, Henryk Foks1 and Krystyna Drewnowska2

Laboratory of Pathophysiology,
1 Department of Organic Chemistry, Medical University of Gdansk, ul. Tuwima 15, 80-210 Gdansk, Poland
2 Bostwick Laboratories, 4355 Innslake Drive, Glen Allen, VA 23060, USA

(Requests for offprints should be addressed to A Rybczynska; Email: aryb{at}amg.gda.pl)

Secretion of parathormone (PTH), the main parathyroid hormone, which is under the control of the calcium sensing receptor, might be inhibited by calcimimetics and stimulated by calcilytics. Parathyroid glands also secrete parathyroid hypertensive factor. Recently, it was shown that calcimimetic NPS R-568 induced decreased blood pressure in spontaneously hypertensive rats (SHR) in the presence of parathyroid glands. Therefore, the aim of this study was to determine whether administration of the calcilytic NPS 2143 provoked an increase of mean arterial blood pressure (MAP) in normotensive rats. We used male Wistar rats anaesthetized with thiopental. Clearance experiments were performed and the effect of bolus, 1 mg/kg body weight i.v. of NPS 2143 on MAP in the presence and absence of thyroparathyroidectomy (TPTX) was monitored continuously. Calcilytic properties of NPS 2143 were confirmed directly by a significant (P < 0.05) increase of plasma PTH concentration, and indirectly by a rise of plasma Ca2+ concentration and urinary fractional phosphate excretion (FE Pi). NPS 2143 administration markedly (P < 0.05) increased MAP, calculated as the difference ( {Delta} ) in MAP between sequential measurements and the time of bolus injection of calcilytic. The observed increase of blood pressure in the NPS 2143 group was also significant (P < 0.05) compared with the control group. Performance of TPTX prevented the hypertensive effect of NPS 2143. We conclude that NPS 2143 is responsible for increased blood pressure in rats in the presence of parathyroid glands.




This article has been cited by other articles:


Home page
HypertensionHome page
S. Smajilovic and J. Tfelt-Hansen
Novel Role of the Calcium-Sensing Receptor in Blood Pressure Modulation
Hypertension, December 1, 2008; 52(6): 994 - 1000.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Smajilovic and J. Tfelt-Hansen
Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system
Cardiovasc Res, August 1, 2007; 75(3): 457 - 467.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.